enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Down 31.5% in February

enGene Holdings Inc. (NASDAQ:ENGN) was the recipient of a significant decrease in short interest in February. As of February 13th, there was short interest totaling 1,501,696 shares, a decrease of 31.5% from the January 29th total of 2,192,033 shares. Based on an average trading volume of 327,514 shares, the days-to-cover ratio is presently 4.6 days. Approximately 2.5% of the shares of the stock are short sold. Approximately 2.5% of the shares of the stock are short sold. Based on an average trading volume of 327,514 shares, the days-to-cover ratio is presently 4.6 days.

enGene Trading Up 0.8%

Shares of NASDAQ ENGN opened at $10.11 on Friday. enGene has a 1-year low of $2.65 and a 1-year high of $12.25. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.09. The company has a 50-day moving average of $9.57 and a two-hundred day moving average of $7.84. The company has a market cap of $677.27 million, a PE ratio of -4.41 and a beta of -0.29.

enGene (NASDAQ:ENGN) last issued its quarterly earnings results on Monday, December 22nd. The company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.18). As a group, equities analysts expect that enGene will post -1.56 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ENGN. Raymond James Financial upgraded shares of enGene from an “outperform” rating to a “strong-buy” rating and set a $27.00 target price on the stock in a research note on Tuesday, November 11th. Weiss Ratings restated a “sell (d-)” rating on shares of enGene in a research report on Friday, January 9th. UBS Group raised their price objective on shares of enGene from $4.00 to $10.00 and gave the stock a “neutral” rating in a report on Wednesday, November 12th. Citizens Jmp boosted their target price on enGene from $18.00 to $21.00 and gave the stock a “market outperform” rating in a report on Wednesday, November 12th. Finally, HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of enGene in a research report on Wednesday, December 3rd. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $23.29.

Institutional Trading of enGene

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. PFS Partners LLC acquired a new position in enGene during the 3rd quarter valued at about $61,000. Cresset Asset Management LLC acquired a new stake in shares of enGene during the 2nd quarter worth approximately $36,000. Raymond James Financial Inc. raised its stake in shares of enGene by 383.6% during the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after buying an additional 7,932 shares during the last quarter. Paloma Partners Management Co acquired a new position in enGene in the second quarter valued at approximately $38,000. Finally, Hudson Bay Capital Management LP bought a new position in enGene in the third quarter valued at approximately $76,000. 64.16% of the stock is currently owned by institutional investors and hedge funds.

About enGene

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.